GGrantIndex
Sort

48,018 grants matching immunotherapy

A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor Immunity

$617,031
Benjamin Greenbaum · Sloan-Kettering Inst Can Research · U01 · FY2024 · CA

TOX-driven CD8 T cell differentiation and dysfunction in tumors

$617,017
Andrea Schietinger · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

Project 1: Durable impact of COVID on innate and adaptive immunity

$616,990
Michela Locci · Massachusetts General Hospital · U19 · FY2024 · AI

Molecular Targeted Photoimmunotherapy for Bladder Cancer

$616,957
Piyush Agarwal · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Leadership, Planning and Evaluation

$616,942
Steven E Artandi · Stanford University · P30 · FY2022 · CA

Neuro-immune modulation of pain in health and disease

$616,920
Christopher Ryan Donnelly · Duke University · R01 · FY2022 · DE

Synthetic Compartments to Rewire Inflammatory Signaling and Augment Immune Cell Function

$616,897
Matthew Charlton Good · University Of Pennsylvania · R56 · FY2025 · EB

Outcomes for CLL patients treated with novel therapy

$616,831
Neil E Kay · Mayo Clinic Rochester · R01 · FY2022 · CA

Evaluation of novel treatments in biochemically recurrent prostate

$616,806
Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Development of multinuclear MRI for image guided therapy of glioma patients

$616,798
Ovidiu C Andronesi · Massachusetts General Hospital · R01 · FY2023 · CA

Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer

$616,757
Maximilian Diehn · Stanford University · R01 · FY2023 · CA

Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer

$616,753
Maximilian Diehn · Stanford University · R01 · FY2022 · CA

(PQ6) Mesenchymal stem cell based and immunocompetent mouse models of HIV/AIDS KSHV-driven sarcomagenesis

$616,751
Noula Dattu Shembade · University Of Miami School Of Medicine · R01 · FY2025 · CA

Microbial-inspired immune-stimulating antibody-toxin conjugate (ATC) for cancer immunotherapy

$616,715
Betty Kim · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Low dose IL-2 and human regulatory T cells

$616,712
Thomas R Malek · University Of Miami School Of Medicine · R01 · FY2018 · AI

DESIGNING EFFECTIVE ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK PEDIATRIC MEDULLOBLASTOMA VIA A RATIONAL COMBINATION WITH MRI-GUIDED FOCUSED ULTRASOUND

$616,710
Children'S Research Institute · · FY2024 · Defense Health Agency

Ultrasensitive kinase biosensors for multiplex imaging of coordinated spatiotemporal signaling in cancer-immune interactions

$616,686
Jin Zhang · University Of California, San Diego · R01 · FY2024 · CA

Immune correlates of acute HBV recovery with and without HIV

$616,491
Chloe L Thio · Johns Hopkins University · R01 · FY2018 · AI

Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation

$616,432
Don J Diamond · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA

Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy

$616,381
Cheng Zhu · Georgia Institute Of Technology · U01 · FY2023 · CA

Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics

$616,273
Stylianos Bournazos · Rockefeller University · R01 · FY2021 · CA

Spatially resolved, single cell biomarkers of B cell lymphoma

$616,249
Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2022 · CA

Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver Cancer

$616,121
James S Duncan · Yale University · R01 · FY2022 · CA

First-in-Class CD206 Agonist for Immunologically Cold Solid Organ Cancers

$616,056
Sharie Haugabook · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR

Novel Approaches to Targeting Cancers Associated with VHL Mutations

$615,955
Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA